contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


inside-information-orion-upgrades-full-year-outlook-for-2024-1

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Kiitos selvennyksestä, ts. eri tyyppisiin kipuihin tuota VX548 tutkineet, neuropaattinen kipuhan on pitkäaikainen terveyspulma ja siten lääke olisi pitkäaikaiskäyttöön. Orionilla tuo erottelu eri kipukategorioihin ei tainnut tulla edes ajankohtaiseksi kun jo giljotiini katkaisi hankkeen.

Sama lääke, eri käyttöaihe, vaikka hermokivusta onkin kyse. Keksivät juuri samalla uudelleen, että placebovaikutus on tilastollisesti merkitsevä kivunlievityksessä. Aikovatko testata seuraavaksi Placebo Fortea? Jonkinlaisen varjon tuo heittää jo faasi 3 tuloksiinkin, vaikka ei niitä ehkä poiskaan voi ottaa. Sanoi kateellinen Orionin omistaja. Vaikea vaikutusreitti näköjään, Orion sammutti valot onneksiko aikaisin.

Kappas. Hieman nyt ihmetyttää että Vertexillä faasi2:ssa tuo lääke, sillä käsittääkseni firmalla on faasi3:sta lupaavia tuloksia tuottanut VX-548 ja siitähän uutisoitiin jo vuosi sitten. Vai onko niin että Vertex on useampaa NaV1.8 -teeman molekyyliä rinnakkain kehittämässä syystä tai toisesta?

Vertexin NaV1.8-lääke suzetrigine sai niheän tuloksen faasi 2:sta: https://news.vrtx.com/news-releases/news-release-details/vertex-announces-results-phase-2-study-suzetrigine-treatment Vertexin osake -13% pressä. Orionhan lopetti oman NaV1.8-lääkkeensä kehittämisen lokakuussa.

Tässä on Antin kommentit Orionin tuoreesta yhteistyöstä.                    Inderes              Orion ja Abilita Therapeutics tutkimusyhteistyöhön - Inderes    Orion tiedotti keskiviikkona tehneensä sopimuksen Abilita Therapeuticsin kanssa tutkimusyhteistyöstä ja lisenssisopimusoptiosta vasta-aineiden kehittämiseksi syövän ja kivun hoitoon.

Tässä pisti silmään myös se, että kipu on mukana eikä sitä ole äskettäisen tutkimuspettymyksen takia heitetty pois. Pidellään👍                   Tärkeimmät talousuutiset | Kauppalehti – 18 Dec 24              Orion aloittaa tutkimusyhteistyön yhdysvaltalaisen Ablita Therapeuticsin kanssa    Yhteistyössä hyödynnetään Abilitan kehittämää Enabled Membrane Protein -teknologiaa.

Redeyen analyytikon mukaan (sisältö kirjautumisen takana) lunastus kertoo ennen kaikkea Alligatorin hankalasta taloudellisesta tilanteesta. Käteispula. Orion saattoi saada siis potentiaalisesti lupaavat lääkekandidaatit edullisesti, mutta aika näyttää, onko niistä mihinkään. 1,75 miljonaa euroa per hankittu aihio ei kuulosta paljolta.  We have valued the deal with Orion at SEK165m, which is a best estimate since we do not know the distribution of the milestone payments, the royalty rate etc. However, the sales price appears low and, we believe, testifies to a lack of liquidity at Alligator and a difficult financial situation.                    redeye.se              Alligator Bioscience: Divestiture of Orion Programmes    Redeye comments on Alligator's sale of two bispecific antibodies to Orion, which were being developed by the latter under a licensing agreement.

Orion

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full...

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion’s product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year. Due to these reasons, Orion upgrades the full-year outlook for 2024. The outlook for 2024 includes one Nubeqa® sales-related milestone payment of EUR 70 million which is included in both the net sales outlook and the operating profit outlook. Orion expects to record this milestone payment in Q3 2024. New full-year outlook, provided on 11 September 2024 Net sales are estimated to be EUR 1,470 million to EUR 1,510 million. Operating profit is estimated to be EUR 370 million to EUR 400 million. Previous full-year outlook, provided on 1 July 2024 Net sales are estimated to be EUR 1,440 million to EUR 1,480 million. Operating profit is estimated to be EUR 350 million to EUR 380 million. Orion Corporation <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tbody><tr><td style="width:18.52%;;vertical-align: top ;">Liisa Hurme President and CEO</td><td style="width:3.24%;;vertical-align: top ;">&nbsp;&nbsp;&nbsp;</td><td style="width:18.52%;;vertical-align: top ;">Olli Huotari SVP, Corporate Functions</td><td style="width:9.72%;;vertical-align: top ;">&nbsp;</td></tr></tbody></table> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact person: Tuukka Hirvonen, Investor Relations, Orion Corporation tel. +358 10&nbsp;426 2721&nbsp; Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland <a href="https://www.globenewswire.com/Tracker?data=IgtjWJBS75oB9s6lc-vyvMjOKQWdEEhJdnXJOdVlzX1pnE29eIptCDaP9sz31xKQk4bWBwqccPxelB9wk8_JfjZLilR-8Sz64NwKMKyDiFA=">http://www.orion.fi/en</a> <a href="https://www.globenewswire.com/Tracker?data=IgtjWJBS75oB9s6lc-vyvMtU9taW31eRnBeGb18v0EXugSyfBvkKzPDhrGfYOVCGZUk59pa0pijYn32QbyEh1ksVUiasP2ZFlRdHq06kKoIFL2Qd16HUeHQXOxg9wX92">http://www.twitter.com/OrionCorpIR</a> Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&amp;D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDk5MTE1MSM0MDE5NDI2MzgjMjAwMTk2Mw=="> <img src="https://ml-eu.globenewswire.com/media/OWQ5YmYwNzktOWVhOS00Y2VkLWI2MDUtNzhiNWMzYzg3M2VmLTEwMTM1MzY=/tiny/Orion-Oyj.png">

Stay up to date with our newsletter